---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: PHA121-C001"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: PHA121-C001. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 34 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence/pha121-c001"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: PHA121-C001

<a id="heading-3.1.4"></a>

## 3.1.4 PHA121-C001

<a id="heading-3.1.4.1"></a>

### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

#### Safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants

> “PHA121-C001 was a randomized, double-blind, placebo-controlled, single ascending dose and proof-of-mechanism study to examine the safety, tolerability, PK and PD of orally administered PHA121 in healthy subjects.”

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)

<a id="topic-3.1.4.1-2"></a>

#### Proof of mechanism through bradykinin challenge

> “Randomized, double-blind, placebo-controlled, single ascending dose to assess safety and proof-of-concept through BK-challenge”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

> “The effect of PHA-022121 cardiovascular changes induced by bradykinin (BK) such as blood pressure (systolic, SBP; diastolic, DBP; mean, MAP), heart rate (HR) and cardiac output (CO) was evaluated in a proof-of-concept study in healthy volunteers.”

Source: [Derendorf et al. (2020)](https://ir.pharvaris.com/static-files/33217945-6893-4f49-8a93-c80ea6fb2a31)

<a id="heading-3.1.4.2"></a>

### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

#### Entry into clinical development with a phase 1 trial in 2019

> “The increase in research and development expenses in 2019 compared to 2018 was due to the progression of PHA121 into clinical development, with a Phase 1 clinical trial initiated in 2019”

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)

<a id="topic-3.1.4.2-2"></a>

#### Completion reported in November 2020

> “Data from a recently completed single-ascending-dose Phase 1 study in healthy volunteers, as well as in vitro and ex vivo models, demonstrate rapid exposure and predictable linear pharmacokinetics.”

Source: [Pharvaris ACAAI 2020 press release (2020)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-presents-clinical-data-acaai-2020-demonstrating-safety)

<a id="topic-3.1.4.2-3"></a>

#### Study status in the annual report

> “Single ascending dose (SAD)”
> “Completed”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="heading-3.1.4.3"></a>

### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

#### Double-blind, placebo-controlled, single ascending dose, first-in-human design

> “PHA-022121 was administered as oral solution in a double-blind placebo-controlled single ascending dose first-in-human study in healthy volunteers”
> “Safety was assessed by physical examination, vital signs, adverse events, safety laboratory and electrocardiogram (ECG) until 72 h post-dosing.”

Source: [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b)

<a id="topic-3.1.4.3-2"></a>

#### Cohorts: pharmacokinetic part 1 and pharmacodynamic part 2

| Cohort | Participants |
| --- | --- |
| Part 1 (PK), 1 mg, fasted | “N=6” |
| Part 1 (PK), 2 mg, fasted | “N=6” |
| Part 1 (PK), 4.5 mg, fasted | “N=6” |
| Part 1 (PK), 12 mg, fasted | “N=6” |
| Part 1 (PK), 22 mg, fasted | “N=6” |
| Part 1 (PK), 22 mg, after high-calorie, high-fat breakfast | “N=6” |
| Part 1 (PK), placebo | “N=12” |
| Part 2 (PD), 12 mg, fasted | “N=8” |
| Part 2 (PD), 22 mg, fasted | “N=8” |
| Part 2 (PD), placebo | “N=4” |

Source: [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b)

<a id="topic-3.1.4.3-3"></a>

#### Bradykinin challenge schedule

> “Bradykinin was injected intravenously before PHA121 to calibrate each subject’s response, and then at 1, 4, 8, 12 and 24 hours after dosing with PHA121. We monitored cardiovascular responses at each time point (see figure above). At the same time, blood samples were drawn for PK assessment.”

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)

<a id="topic-3.1.4.3-4"></a>

#### Study code: C001 in the annual report, PHA121-C001 in the registration statement

> “C001”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

> “PHA121-C001 (SAD and BK challenge / SAD-POM)”

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)

<a id="heading-3.1.4.4"></a>

### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

#### Healthy volunteers

> “The data in both posters present the pharmacokinetic (PK), pharmacodynamic (PD), and safety profiles of PHA121 in healthy volunteers.”

Source: [Pharvaris ACAAI 2020 press release (2020)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-presents-clinical-data-acaai-2020-demonstrating-safety)

<a id="heading-3.1.4.5"></a>

### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

#### Single oral doses as an oral solution

> “PHA121 was administered as an oral solution in a double-blind placebo-controlled single-ascending-dose first-in-human study in healthy volunteers.”

Source: [Pharvaris ACAAI 2020 press release (2020)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-presents-clinical-data-acaai-2020-demonstrating-safety)

<a id="topic-3.1.4.5-2"></a>

#### Bradykinin challenge cohorts: 12 and 22 mg

> “PHA-022121 (12 and 22 mg) was administered orally (p.o.) to 16 healthy volunteers.”
> “Bradykinin injections were administered to induce cardiovascular responses.”

Source: [Derendorf et al. (2020)](https://ir.pharvaris.com/static-files/33217945-6893-4f49-8a93-c80ea6fb2a31)

<a id="topic-3.1.4.5-3"></a>

#### Fed condition: 22 mg after a high-calorie, high-fat breakfast

> “§ after high caloric/high fat (HCHF) breakfast”

Source: [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b)

<a id="heading-3.1.4.6"></a>

### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

#### 3.1.4.6.1 Rationale for Using Safety and Tolerability as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

##### Safety and pharmacokinetics assessed through 72 hours

> “Both PK parameters and safety were assessed until 72 hours post-dosing.”

Source: [Pharvaris ACAAI 2020 press release (2020)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-presents-clinical-data-acaai-2020-demonstrating-safety)

<a id="topic-3.1.4.6.1-2"></a>

##### Bradykinin challenge as a surrogate for dose selection

> “The bradykinin challenge is administered at specific intervals after the PHA121 or placebo dose, and the inhibition of bradykinin-induced hemodynamic effects is a validated surrogate assessment that was used to select the dose in the original development program for icatibant, as reviewed by FDA and EMA.”
> “More precisely, it was shown that icatibant plasma concentrations with a 75% probability to be above EC50 and a 50% probability to be above EC85 correlate with therapeutic efficacy.”

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)

> “Dampened BK-induced effects are closely associated with successful therapeutic outcome for icatibant”

Source: [Derendorf et al. (2020)](https://ir.pharvaris.com/static-files/33217945-6893-4f49-8a93-c80ea6fb2a31)

<a id="topic-3.1.4.6.1-3"></a>

##### Pharmacodynamic outcome definition

> “The pharmacodynamic (PD) outcome variables were measured from 5 min before until 5 min after each BK bolus. A % inhibition-of-the-baseline average-to-peak effect was calculated and used as the PD outcome.”

Source: [Derendorf et al. (2020)](https://ir.pharvaris.com/static-files/33217945-6893-4f49-8a93-c80ea6fb2a31)

<a id="topic-3.1.4.6.1-4"></a>

##### Use of the bradykinin challenge results for later studies

> “Demonstrated proof-of-mechanism”
> “Provided justification of dose selection for on-demand studies”
> “Provided guidance for prophylactic development”

Source: [Lesage et al. (2021)](https://ir.pharvaris.com/static-files/76beb63f-4ccf-482a-933d-d2b47ec4e09d)

<a id="heading-3.1.4.7"></a>

### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

#### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

##### Participants receiving deucrictibant and placebo

> “A total of 52 subjects received single ascending oral doses of PHA121 up to 22 mg. The 16 remaining subjects received placebo.”

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)

<a id="topic-3.1.4.7.1-2"></a>

##### Bradykinin challenge participants

> “Two doses (12 and 22 mg) of PHA121 were administered orally to 16 healthy volunteers, followed by bradykinin challenges to induce brief hemodynamic responses.”

Source: [Pharvaris ACAAI 2020 press release (2020)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-presents-clinical-data-acaai-2020-demonstrating-safety)

<a id="heading-3.1.4.7.2"></a>

#### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

##### Pharmacokinetic and pharmacodynamic modeling of the bradykinin challenge cohorts

> “PHA-022121-induced changes of these BK responses were evaluated with a nonlinear mixed-effect PK/PD model. The results were compared to published results obtained from icatibant (3). PK was analyzed using a two-compartment body model with first-order oral absorption and a lag time. For the PK/PD model a simple Emax-model with a direct link was utilized.”

Source: [Derendorf et al. (2020)](https://ir.pharvaris.com/static-files/33217945-6893-4f49-8a93-c80ea6fb2a31)

<a id="topic-3.1.4.7.2-2"></a>

##### Pharmacokinetic summary statistics

> “# means (standard deviation),  median (range) for tmax”

Source: [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b)

<a id="heading-3.1.4.8"></a>

### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

#### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

##### No withdrawals due to adverse events

> “No adverse event, or AE, was reported as serious, no premature withdrawals due to AEs occurred and no severe AEs were reported.”

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)

<a id="heading-3.1.4.8.2"></a>

#### 3.1.4.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.4.8.3"></a>

#### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

##### Pharmacokinetics: rapid absorption, dose proportionality, and half-life

> “PHA-022121 was very rapidly absorbed and reached peak plasma levels within 30 to 60 minutes after dosing in all subjects under fasted conditions. The systemic exposure was dose proportional with a mean t1/2 ranging from 3.5 to 5.6 h between doses.”

Source: [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b)

> “Less than 1% of the dose was excreted unchanged in urine within 72 hours after administration.”

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)

<a id="topic-3.1.4.8.3-2"></a>

##### Pharmacokinetic parameters by dose (N=6 per dose)

| Parameter | 1 mg | 2 mg | 4.5 mg | 12 mg | 22 mg | 22 mg after HCHF breakfast |
| --- | --- | --- | --- | --- | --- | --- |
| Cmax, ng/mL, mean (SD) | “11.1 (4.03)” | “19.8 (3.70)” | “32.9 (7.66)” | “97.3 (28.1)” | “213 (49.5)” | “145 (56.2)” |
| C0.25h, ng/mL, mean (SD) | “5.99 (4.28)” | “12.9 (8.10)” | “13.0 (7.00)” | “60.3 (40.6)” | “143 (85.9)” | “48.3 (53.9)” |
| AUClast, ng.h/mL, mean (SD) | “33.0 (25.9)” | “66.0 (27.0)” | “129 (56.5)” | “369 (194)” | “681 (113)” | “1015 (490)” |
| t1/2, h, mean (SD) | “3.49 (1.32)” | “4.26 (1.91)” | “4.36 (1.29)” | “4.25 (0.831)” | “5.61 (0.707)” | “5.31 (1.54)” |

Source: [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b)

<a id="topic-3.1.4.8.3-3"></a>

##### Food effect at 22 mg

> “Administration of the 22 mg dose with a HCHF breakfast led to a 32% lower Cmax, a 49% higher AUClast, and a delay of median tmax by approximately 2 h.”

Source: [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b)

> “after a 22 mg dose, the mean Cmax of PHA121 was lower (~32%) while AUCinf was higher (~ 42%) when PHA121 was administered after a high calorie, high-fat breakfast (fed conditions) compared to administration under fasted conditions.”

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)

<a id="topic-3.1.4.8.3-4"></a>

##### Time to and duration above therapeutic threshold concentrations

> “Plasma levels for PHA-022121 reached therapeutic efficacious threshold concentration (estimated EC50 2.4 ng/mL and EC85 13.8 ng/mL ; see poster P151 (2)) within 15 min for all doses and were maintained for approximately 12 h with doses of 12 and 22 mg.”

Source: [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b)

<a id="topic-3.1.4.8.3-5"></a>

##### Bradykinin challenge: potency relative to icatibant

| Composite average | PHA121 | Icatibant |
| --- | --- | --- |
| EC50 (ng/mL) | “2.4” | “9.5” |
| EC85 (ng/mL) | “13.8” | “53.8” |

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)

> “Adjusting for the differences between molecular weight and plasma protein binding, we found that PHA121 is 24-fold more potent (170 pM) in the bradykinin challenge than icatibant (4.1 nM) on a molecule-by-molecule basis, consistent with our preclinical in vitro measurements.”

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)

<a id="topic-3.1.4.8.3-6"></a>

##### Bradykinin challenge: modeled duration of effect compared with icatibant 30 mg

| Response | Icatibant 30 mg (s.c.) | PHA121 12 mg (oral) | PHA121 22 mg (oral) |
| --- | --- | --- | --- |
| Diastolic blood pressure, time (h) above EC50 at a 75% confidence level | “6” | “11.5” | “14” |
| Mean arterial blood pressure, time (h) above EC50 at a 75% confidence level | “6” | “12” | “15.5” |
| Heart rate, time (h) above EC50 at a 75% confidence level | “6.5” | “10” | “13” |
| Diastolic blood pressure, time (h) above EC85 at a 50% confidence level | “5.5” | “7.5” | “10” |
| Mean arterial blood pressure, time (h) above EC85 at a 50% confidence level | “5.5” | “7” | “10” |
| Heart rate, time (h) above EC85 at a 50% confidence level | “5.5” | “6.5” | “9.5” |

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)

<a id="topic-3.1.4.8.3-7"></a>

##### Authors' conclusions on the bradykinin challenge

> “The investigated single oral doses of PHA-022121 (12 and 22 mg) provide equivalent BK-antagonism for a longer time than a 30 mg s.c. icatibant injection.”

Source: [Derendorf et al. (2020)](https://ir.pharvaris.com/static-files/33217945-6893-4f49-8a93-c80ea6fb2a31)

> “The BK challenge demonstrated that PHA121 potently blocks the effects of bradykinin-induced hemodynamic changes and provided the robust rationale for dose selection in future on-demand and prophylactic HAE trials.”

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)

<a id="heading-3.1.4.8.4"></a>

#### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

#### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

##### Adverse events by dose group

| Dose group | Participants | Any AE, n (%) | Any related AE | Any severe AE | Any serious AE |
| --- | --- | --- | --- | --- | --- |
| 1 mg, fasted | “N=6” | “2 (33.3%)” | “0” | “0” | “0” |
| 2 mg, fasted | “N=6” | “1 (16.7%)” | “0” | “0” | “0” |
| 4.5 mg, fasted | “N=6” | “1 (16.7%)” | “0” | “0” | “0” |
| 12 mg, fasted | “N=14” | “5 (35.7%)” | “2 (14.3%)” | “0” | “0” |
| 22 mg, fasted | “N=14” | “2 (14.3%)” | “1 (7.1%)” | “0” | “0” |
| 22 mg after HCHF breakfast | “N=6” | “1 (16.7%)” | “0” | “0” | “0” |
| Placebo | “N=16” | “5 (31.3%)” | “1 (6.3%)” | “0” | “0” |

Source: [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b)

<a id="topic-3.1.4.8.5-2"></a>

##### Adverse event incidence with deucrictibant and placebo

> “In total 17 AEs were reported by 12 out of 52 subjects on active drug versus 7 AEs in 5 out of 16 placebo treated subjects. No serious or severe adverse events occurred. All related adverse events were of mild intensity and resolved rapidly.”
> “No clinically significant changes in safety laboratory parameters, vital signs and ECG parameters were observed.”

Source: [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b)

> “In total, 17 AEs were reported by 12 out of 52 subjects (23%) on study drug versus 7 AEs in 5 out of 16 (31%) placebo-treated subjects.”

Source: [Pharvaris ACAAI 2020 press release (2020)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-presents-clinical-data-acaai-2020-demonstrating-safety)

<a id="topic-3.1.4.8.5-3"></a>

##### Treatment-related gastrointestinal adverse events and blood pressure

> “In addition, no clinically relevant fluctuations of blood pressure and no orthostatic hypotension linked to PHA121 groups occurred.”
> “Treatment-related AEs were reported for three subjects who received PHA121 (12 or 22 mg), all within the gastrointestinal system and of mild severity: upper abdominal pain, vomiting, and nausea.”

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)

<a id="topic-3.1.4.8.5-4"></a>

##### Pooled safety across two single ascending dose studies (1 to 50 mg)

> “PHA-022121 was orally administered in two double-blind, placebo-controlled single ascending dose studies (range 1-50 mg) with pharmacokinetic (PK) and safety follow-up for 72 h.”
> “Adverse events (AEs) were reported by 25% of the subjects in the combined group of all subjects treated with PHA-022121, identical to the 25% incidence with placebo.”
> “All AEs were mild or moderate and subsided rapidly and completely.”

Source: [Crabbé et al. (2021)](https://ir.pharvaris.com/static-files/a5937e81-635a-4808-b099-3a049c87c51b)

<a id="heading-3.1.4.9"></a>

### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

#### Summary

- PHA121-C001 enrolled healthy volunteers, who received single doses up to 22 mg given as an oral solution.
- Pharmacokinetic cohorts had six participants per dose, and the food effect was assessed in one cohort of six participants at 22 mg. The higher AUCinf after a high-calorie, high-fat breakfast was reported as “mainly caused by one outlier”, and the AUC increase is reported as 49% and as 42% in different documents.
- The pharmacodynamic evidence comes from a bradykinin challenge in 16 healthy volunteers receiving 12 or 22 mg, a surrogate used for icatibant dose selection, and the results were compared with published icatibant results.
- Safety was followed for 72 hours after a single dose.
- The results are reported in two posters described in a company press release and in the company's registration statement.

Source: [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm); [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b); [Crabbé et al. (2021)](https://ir.pharvaris.com/static-files/a5937e81-635a-4808-b099-3a049c87c51b); [Derendorf et al. (2020)](https://ir.pharvaris.com/static-files/33217945-6893-4f49-8a93-c80ea6fb2a31); [Pharvaris ACAAI 2020 press release (2020)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-presents-clinical-data-acaai-2020-demonstrating-safety)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
